Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solanezumab safety in mild-to-moderate Alzheimer's disease and healthy volunteers
NCT00329082Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2006
- Primary completion
- May 2008
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of solanezumab in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Started May 2006; status: completed.
02
Drugs
solanezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00329082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00329082.